Literature DB >> 33685363

WIPI1 promotes fission of endosomal transport carriers and formation of autophagosomes through distinct mechanisms.

Maria Giovanna De Leo1, Philipp Berger2, Andreas Mayer1.   

Abstract

Autophagosome formation requires PROPPIN/WIPI proteins and monophosphorylated phosphoinositides, such as phosphatidylinositol-3-phosphate (PtdIns3P) or PtdIns5P. This process occurs in association with mammalian endosomes, where the PROPPIN WIPI1 has additional, undefined roles in vesicular traffic. To explore whether these functions are interconnected, we dissected routes and subreactions of endosomal trafficking requiring WIPI1. WIPI1 specifically acts in the formation and fission of tubulo-vesicular endosomal transport carriers. This activity supports the PtdIns(3,5)P2-dependent transport of endosomal cargo toward the plasma membrane, Golgi, and lysosomes, suggesting a general role of WIPI1 in endosomal protein exit. Three features differentiate the endosomal and macroautophagic/autophagic activities of WIPI1: phosphoinositide binding site II, the requirement for PtdIns(3,5)P2, and bilayer deformation through a conserved amphipathic α-helix. Their inactivation preserves autophagy but leads to a strong enlargement of endosomes, which accumulate micrometer-long endosomal membrane tubules carrying cargo proteins. WIPI1 thus supports autophagy and protein exit from endosomes by different modes of action. We propose that the type of phosphoinositides occupying its two lipid binding sites, the most unusual feature of PROPPIN/WIPI family proteins, switches between these effector functions.Abbreviations: EGF: epidermal growth factorEGFR: epidermal growth factor receptorKD: knockdownKO: knockoutPtdIns3P: phosphatidylinositol-3-phosphatePtdIns5P: phosphatidylinositol-5-phosphatePtdIns(3,5)P2: phosphatidylinositol-3,5-bisphosphateTF: transferrinTFRC: transferrin receptorWT: wildtype.

Entities:  

Keywords:  Autophagy; EGF receptor; PROPPIN; WIPI proteins; autophagosome; endosomal transport carrier; endosome; lysosome; transferrin receptor; vacuole

Mesh:

Substances:

Year:  2021        PMID: 33685363      PMCID: PMC8632285          DOI: 10.1080/15548627.2021.1886830

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


Introduction

Autophagy depends on a complex protein machinery that is recruited to phagophores, the sites of autophagosome formation. It allows the growth of a phagophore at this site, recruits cargo into the nascent autophagosome and mediates its closure [1]. The formation of autophagosomes depends on phosphatidylinositol-3-phosphate (PtdIns3P) or phosphatidylinositol-5-phosphate (PtdIns5P) [2-5]. Phosphatidylinositol-3,5-bisphosphate (PI [3,5]P2) appears to be dispensable for formation of autophagosomes but supports their fusion with lysosomes [6-9]. Important binders of these lipids at the phagophore are PROPPIN/WIPI proteins, beta-propellers binding phosphoinositides. They constitute a family of conserved proteins with three members present in yeast (Atg18, Atg21, and Hsv2), and four members in mammals (WIPI1, WIPI2, WDR45B/WIPI3 and WDR45/WIPI4) [10,11]. During autophagy, WIPI1 and WIPI2 localize to autophagic membranes [12,13]. WIPI2 interacts with several factors driving the formation of autophagosomes, such as ATG16L1 and ATG7 [14-17]. Its knockdown inhibits autophagy. WIPI1 interacts with WIPI2 and ATG16L1, but the WIPI1-ATG16L1 interaction appears to be weak and it is was proposed that it might occur indirectly through WIPI2 [17,18]. WIPI1 knockdown reduces virus-induced autophagy, suggesting that it has an important function at the phagophore [19]. WDR45B/WIPI3 and WDR45/WIPI4 were proposed to be part of a signaling complex involved in the induction autophagy [18] and to tether the phagophore membrane to the ER [20-22]. PROPPINs bind the phagophore membrane through two lipid binding sites, which have affinities for PtdIns3P, PtdIns5P and PtdIns(3,5)P2 [3,10,12,23-26]. A major open question is why there are two lipid binding sites, whether they serve as mere membrane anchors, or whether they can confer distinct functions to the WIPI proteins, which might then be defined by the type of phosphoinositide bound. Aside from their location at phagophores, WIPI1 and WIPI2 also associate with endosomes [27,28]. Here, WIPI2 interacts with the endosomal marker RAB11, a RAB-GTPase that also has an impact on autophagosome formation [29]. Futher molecular links between the autophagic machinery and endosomes were provided by the WIPI1 and WIPI2 interactors ATG16L1 and ATG7, which not only promote autophagy but also influence EGFR (epidermal growth factor receptor) trafficking. This led to the suggestion that autophagy might improve endosomal sorting capacity by removing damaged endosomes [30]. Furthermore, ATG9, a membrane-integral component of the autophagic machinery, was proposed to shuttle between endosomal compartments and the phagophore [28]. Thus, it is possible that endosomal trafficking and autophagosome biogenesis are intimately connected and share some components, among them the WIPI proteins, but it is not known whether these proteins perform equivalent activities in both processes or whether their effects on endosomal sorting are mere consequences of the autophagy of endosomes. Cells internalize plasma membrane components and extracellular material, such as receptors, transporters, growth factors and solute molecules, by endocytosis. Endocytic vesicles pinch off from the plasma membrane and deliver their cargoes to early endosomes [31]. From there, they can be channeled into several trafficking routes: They can recycle back to the plasma membrane [32-34], move to juxtanuclear endocytic recycling compartments, head for the trans-Golgi network [35], or they can be sorted into multivesicular bodies and degradative lysosomal compartments [36-38]. Arrival of membrane from the cell surface must be balanced by endosomal exit and recycling pathways. These employ tubulo-vesicular endosomal transport carriers and allow cells to control the size and composition of endosomes as well as their signaling properties [39-41]. Important steps in the generation of transport carriers are cargo recruitment, the shaping of the membrane into tubular-vesicular structures, and its constriction and fission. Numerous components that are required for the formation of endosomal transport carriers have been identified, such as the retromer, retriever and CCC complexes, sorting nexins and the WASH complex [42-48]. While structural analyses of retromer have provided us with first impressions of how coats might shape endosomal transport carriers [49,50], their detachment from the endosome has remained very poorly understood. Several factors could contribute. The formation of tubular membranes generates membrane tension, which itself can favor fission [51,52]. In addition, fission can be promoted by the generation of force and friction through the cytoskeleton [43-45,53], and by dedicated fission factors, such as dynamin-like GTPases [54]. During the division of yeast vacuoles, the PROPPIN Atg18 was proposed to drive membrane fission [55,56]. Atg18 carries a hydrophobic CD-loop on blade 6, which must insert into the membrane in order to allow membrane binding [23-26,57,58]. Concomitant folding of this loop into an amphipathic α-helix allows Atg18 to drive membrane fission, e.g. of synthetic giant unilamellar liposomes [55]. Since the potential to form an amphipathic α-helix is conserved among PROPPINs, also other members of this family might carry membrane fission activity. This, however, has not yet been investigated and it has remained unclear whether WIPI proteins provide such an activity on endosomal trafficking pathways. Inactivation of WIPI1 changes the distribution of M6PR (mannose-6-phosphate receptor, cation dependent) in mammalian cells cell and leads to more elaborated early endosomes, suggesting a function in endosomal membrane traffic [27]. However, trafficking reactions consist of multiple steps, which employ different protein machineries, and it has not been resolved whether WIPI1 participates in the formation, fission, fusion or displacement of endosomal transport carriers. The formation of such carriers depends on PtdIns(3,5)P2, which was proposed to promote their fission [59], but the responsible PtdIns(3,5)P2 effectors have not been identified. WIPI1 is a candidate, because it binds PtdIns3P, PtdIns(3,5)P2, and PtdIns(5)P [3,25,27,60,61]. The lipid binding sites of PROPPINs have often been inactivated by substituting two conserved arginine residues within an FRRG motif. Since this motif participates in both lipid-binding sites [10,12,27,62,63], these substitutions cannot reveal whether the two lipid binding sites provide distinct functions to the protein. Purified PROPPINs distinguish only weakly between PtdIns3P and PtdIns(3,5)P2 at the level of their binding affinities [23-25,57,64]. Since PtdIns3P is much more abundant in cells than PtdIns(3,5)P2 it has thus remained unclear whether WIPI proteins mediate PtdIns(3,5)P2 effects in endosomal membrane traffic and which mechanistic role they might perform. In this study, we used WIPI1 as a model to dissect the role of PROPPINs in endosomal membrane traffic, which allowed us to differentiate it from that in autophagy. We identified the trafficking routes affected by WIPI1, determined the subreaction of endosomal trafficking requiring it, and tested whether endosomal trafficking utilizes the same molecular features of WIPI1 as the formation of autophagosomes.

Results

Enlargement of endo-lysosomal compartments in WIPI1-deficient cells

We analyzed the effect of WIPI1 on the localization of two compartment markers, the EEA1 (early endosome antigen 1) and the late endosomal and lysosomal LAMP1 (lysosomal associated membrane protein 1). In line with previous findings [27], siRNA-mediated knockdown of endogenous WIPI1 (WIPI1-KD) led to an increase in both number and size of EEA1-positive early endosomal compartments, as judged by immunofluorescence analysis (Figureure. 1A,B). Western blots showed a corresponding 30–40% increase of EEA1 in these cells (Figure. S1 A). WIPI1 depletion increased also the abundance of LAMP1-positive late endosomes and lysosomes, as assessed by immunofluorescence (Figure 1A,C), and led to a 30% increase in LAMP1 signals on immunoblots (Figure. S1 B). The EEA1 and LAMP1 phenotypes of WIPI1-KD cells were rescued by expressing siRNA-resistant WIPI1 in them, excluding off-target effects of the siRNA. Rescue was not observed with WIPI1[FAAG] [27,63,65], a version of WIPI1 in which two arginines that are critical for both lipid-binding sites have been substituted by alanine (Figure 1D,E). HK2 cells from which WIPI1 had been entirely removed through CRISPR-Cas9-mediated knockout ( KO) showed phenotypes that were similar to those of WIPI1 KD cells, but slightly stronger (Figure 1A).
Figure 1.

Loss of WIPI1 alters the endo-lysosomal compartment. (A) Representative images of control (CTR), WIPI1-KD and WIPI1 KO HK2 cells immuno-stained with an anti-EEA1 and with anti-LAMP1 antibodies (scale bars: 10 μm). (B-C) Quantification of cells from (A). The average number per cell of enlarged (diameter >2 μm2) EEA1-positive (B) or LAMP1-positive (C) structures, and of all LAMP1- or EEA1-positive structures was determined for CTR and WIPI1 KD cells. The integrated fluorescence intensity per cell was also measured (right panels). Mean values ± s.d. are shown (D) Rescue of WIPI1 knockdown. Experiment as in (A), with cells expressing an siRNA-resistant allele of wild-type (WIPI1) or of a version with substitutions in the lipid binding sites (WIPI1[FAAG]). EEA1 (red), LAMP1 (magenta) and EGFP-WIPI1 (green) are shown. Scale bars: 10 μm. (E) Quantification of EEA1- and LAMP1-fluorescence from (D). Images were acquired and analyzed as in (B). For (B-C) and (E), 180 cells per condition, pooled from 3 independent experiments, were analyzed. Mean values ± s.d are shown

Loss of WIPI1 alters the endo-lysosomal compartment. (A) Representative images of control (CTR), WIPI1-KD and WIPI1 KO HK2 cells immuno-stained with an anti-EEA1 and with anti-LAMP1 antibodies (scale bars: 10 μm). (B-C) Quantification of cells from (A). The average number per cell of enlarged (diameter >2 μm2) EEA1-positive (B) or LAMP1-positive (C) structures, and of all LAMP1- or EEA1-positive structures was determined for CTR and WIPI1 KD cells. The integrated fluorescence intensity per cell was also measured (right panels). Mean values ± s.d. are shown (D) Rescue of WIPI1 knockdown. Experiment as in (A), with cells expressing an siRNA-resistant allele of wild-type (WIPI1) or of a version with substitutions in the lipid binding sites (WIPI1[FAAG]). EEA1 (red), LAMP1 (magenta) and EGFP-WIPI1 (green) are shown. Scale bars: 10 μm. (E) Quantification of EEA1- and LAMP1-fluorescence from (D). Images were acquired and analyzed as in (B). For (B-C) and (E), 180 cells per condition, pooled from 3 independent experiments, were analyzed. Mean values ± s.d are shown

WIPI1 promotes protein exit from early endosomes toward lysosomes, the Golgi and the plasma membrane

We investigated the requirement of WIPI1 for the recycling pathway from early endosomes to the plasma membrane using TFRC (transferrin receptor) [33,66], and for transfer from early to late endosomes and lysosomes using EGFR [67]. In pulse-chase experiments, control and WIPI1 KO cells were incubated with TF (transferrin) for 60 min at 4°C. This treatment loads TFRC at the surface but prevents its internalization, which is confirmed by the fact that abundant TFRC staining appeared in immunofluorescence analysis of non-permeabilized cells, but hardly any staining was detectable after the plasma membrane had been detergent-permeabilized (Figure 2A,B). The surface of WIPI1 KO cells bound less TF than that of control cells, suggesting that the knockouts carry less TFRC at the cell surface. Shifting TF-loaded cells to 37°C triggers internalization of loaded TFRC (Figure 2A). WIPI1 KO cells internalized bound TF at the same rate as control cells, suggesting that endocytosis of TFRC does not depend on WIPI1. Despite the lower initial presence of TFRC at the surface of WIPI1 KO cells, these cells showed more intracellular TFRC than control cells at the later time points (Figure 2A,B). This suggests that TFRC accumulates inside WIPI1 KO cells rather than being efficiently recycled back to the cell surface.
Figure 2.

WIPI1 does not affect initial TF uptake, but it is crucial for efficient recycling of TFRC. (A) TFRC surface binding. Control and WIPI1 KO cells were serum-starved for 1 h, washed twice in cold PBS with 1% BSA and incubated for 1 h on ice with 50 μg/ml of transferrin. Cells were transferred to 37°C for the indicated periods of time, acid washed and fixed. Fixed cells were stained with antibodies to TFRC (green) and with DAPI (blue), with detergent permeabilization where indicated. Scale bars: 10 μm. (B) Quantification of TFRC-immunofluorescence in permeabilized cells from (a). Regions of interest (ROIs) corresponding to each cell and in some regions outside the cells (background) were manually defined using ImageJ software. Total cell fluorescence was integrated and corrected for background fluorescence. 195 cells per condition, stemming from 3 independent experiments, were analyzed. Mean values ± s.d. (C) TF recycling. Control and WIPI1 KO cells were serum-starved for 1 h and washed twice in cold PBS with 1% BSA. Cells were then incubated at 37°C for 1 h to load them with 100 μg/ml Alexa-Fluor-488-TF (green), followed by a chase at 37°C in fresh complete HEPES-buffered medium. After the indicated periods of time, cells were acid-washed, fixed and stained with DAPI (blue) and antibodies to EEA1 (red). Scale bars: 10 μm. Insets show enlargements of boxed areas. (D) Quantification. TF-fluorescence in the cells from (C) was integrated as described in (B) and expressed as percentage of the control at 0 min of chase. Data are mean values ± s.d.; (n = 3 independent experiments). 100 cells per condition (CTR and WIPI1 KO) were quantified for each experiment

WIPI1 does not affect initial TF uptake, but it is crucial for efficient recycling of TFRC. (A) TFRC surface binding. Control and WIPI1 KO cells were serum-starved for 1 h, washed twice in cold PBS with 1% BSA and incubated for 1 h on ice with 50 μg/ml of transferrin. Cells were transferred to 37°C for the indicated periods of time, acid washed and fixed. Fixed cells were stained with antibodies to TFRC (green) and with DAPI (blue), with detergent permeabilization where indicated. Scale bars: 10 μm. (B) Quantification of TFRC-immunofluorescence in permeabilized cells from (a). Regions of interest (ROIs) corresponding to each cell and in some regions outside the cells (background) were manually defined using ImageJ software. Total cell fluorescence was integrated and corrected for background fluorescence. 195 cells per condition, stemming from 3 independent experiments, were analyzed. Mean values ± s.d. (C) TF recycling. Control and WIPI1 KO cells were serum-starved for 1 h and washed twice in cold PBS with 1% BSA. Cells were then incubated at 37°C for 1 h to load them with 100 μg/ml Alexa-Fluor-488-TF (green), followed by a chase at 37°C in fresh complete HEPES-buffered medium. After the indicated periods of time, cells were acid-washed, fixed and stained with DAPI (blue) and antibodies to EEA1 (red). Scale bars: 10 μm. Insets show enlargements of boxed areas. (D) Quantification. TF-fluorescence in the cells from (C) was integrated as described in (B) and expressed as percentage of the control at 0 min of chase. Data are mean values ± s.d.; (n = 3 independent experiments). 100 cells per condition (CTR and WIPI1 KO) were quantified for each experiment In order to assess the rate of TFRC recycling from endosomes, cells were incubated with Alexa Fluor 488-conjugated TF at 37°C for 60 min, which allows to load the internal compartments with it (Figure 2C,D). Non-internalized TF was removed by washing and the cells were chased in TF-free medium at 37 °C. While control cells showed a progressive decrease in the TF signal down to 10%, due to recycling of the internalized protein back to the cell surface, from where it dissociates, WIPI1 KO cells retained almost 50% of TF in enlarged EEA1-positive endosomes. We used siRNA-mediated knockdowns to test whether TF recycling required also the other three WIPI-proteins as well as Atg2 and Atg16L1, proteins that interact strongly with WIPI2 and weakly or indirectly with WIPI1 [17,18]. The knockdown of all these factors was efficient, reducing their protein amounts by 85–95% (Figure 3A,B). In contrast to the depletion of WIPI1, which reduced recycling of TF to the surface by 50%, depletion of WIPI2, WDR45B/WIPI3, WDR45/WIPI4, ATG2 or ATG16L1 showed only minor effects (Figure 3C,D). These cells recycled 80–90% of TF, close to the value of control cells, which recycled 92% back to the cell surface. Enlargement of endosomal compartments, which is very striking after WIPI1 knockdown, was only weakly evident after WIPI2 knockdown and not observed in the other knockdowns. Thus, WIPI1 promotes the exit of TFRC from early endosomes and its recycling to the plasma membrane. This endosomal activity appears to be largely independent of the other WIPI isoforms and their interactors, such as ATG2 and ATG16L1.
Figure 3.

Influence of the knockdown of WIPI proteins, ATG16L1 and ATG2 on TF recycling. (A) Effects of siRNA treatment on protein levels. HK-2 cells were treated with non-targeting siRNA (CTR) or with siRNA pools to knock down WIPI1, WIPI2, WDR45B/WIPI3, WDR45/WIPI4, ATG2 and ATG16L1 for 72 h. Cell lysates (50 μg/sample) were analyzed by SDS-PAGE and immunoblotted using the indicated antibodies. TUBA/α-tubulin served as a loading control. A representative blot is shown. (B) Quantification of protein levels from 3 independent experiments as in (A). The levels of all proteins were normalized to TUBA/α-tubulin and are expressed as percentage of the CTR signal. (C) TF recycling. Control and cells depleted of the indicated proteins were serum-starved for 1 h and washed twice in cold PBS with 1% BSA. Cells were then incubated at 37°C for 1 h to load them with 100 μg/ml Alexa Fluor 488-TF (green), followed by a chase at 37°C in fresh complete HEPES-buffered medium. After 1 hour, cells were acid-washed, fixed and stained with DAPI (blue) and antibodies to EEA1 (red). Scale bars: 10 μm. (D) Quantification of TF recycling. TF-fluorescence in the cells from (A) was integrated as described in Figure 2D and expressed as percentage of the control at 0 min of chase. Data are mean values ± s.d.; (n = 3 independent experiments). 100 cells per condition were quantified for each experiment

Influence of the knockdown of WIPI proteins, ATG16L1 and ATG2 on TF recycling. (A) Effects of siRNA treatment on protein levels. HK-2 cells were treated with non-targeting siRNA (CTR) or with siRNA pools to knock down WIPI1, WIPI2, WDR45B/WIPI3, WDR45/WIPI4, ATG2 and ATG16L1 for 72 h. Cell lysates (50 μg/sample) were analyzed by SDS-PAGE and immunoblotted using the indicated antibodies. TUBA/α-tubulin served as a loading control. A representative blot is shown. (B) Quantification of protein levels from 3 independent experiments as in (A). The levels of all proteins were normalized to TUBA/α-tubulin and are expressed as percentage of the CTR signal. (C) TF recycling. Control and cells depleted of the indicated proteins were serum-starved for 1 h and washed twice in cold PBS with 1% BSA. Cells were then incubated at 37°C for 1 h to load them with 100 μg/ml Alexa Fluor 488-TF (green), followed by a chase at 37°C in fresh complete HEPES-buffered medium. After 1 hour, cells were acid-washed, fixed and stained with DAPI (blue) and antibodies to EEA1 (red). Scale bars: 10 μm. (D) Quantification of TF recycling. TF-fluorescence in the cells from (A) was integrated as described in Figure 2D and expressed as percentage of the control at 0 min of chase. Data are mean values ± s.d.; (n = 3 independent experiments). 100 cells per condition were quantified for each experiment In contrast to these observations, an earlier study proposed that the autophagic machinery, including the WIPI proteins and ATG16L1, promotes endosomal trafficking by autophagic removal of damaged endosomes [30]. This discrepancy probably reflects differences in the approach. Fraser et al. performed all their assays in starving cells, where autophagy is crucial for vitality and survival, whereas we analyzed growing cells in rich media, and in a different cell line. Thus, our observations should not be considered as contradictory to this study. We next assayed transport from endosomes to the biosynthetic/secretory pathway through Shiga toxin B-subunit. This protein transits from the plasma membrane to the ER via early endosomes and the Golgi apparatus, circumventing the late endocytic pathway [68]. Cy3-labeled Shiga toxin was accumulated in early endosomes by incubating the cells at 19.5°C. Its chase was triggered by shifting the cells to 37°C. These incubations had been performed in the presence of Alexa Fluor488-conjugated TF to label early and recycling endosomes. Initially, TF and Shiga toxin colocalized extensively. But already after 10 min of chase, most of the Shiga toxin in control cells had moved to compartments showing the typical perinuclear morphology of the Golgi [68], while much of the TF had been recycled back to the cell surface. After 30 min, virtually no Shiga toxin remained in small endosomal structures. By contrast, WIPI1 KO cells showed a strong delay in the arrival of Shiga toxin to the Golgi complex and 50% of colocalization between Shiga toxin B-subunit and TF was retained even after 30 min of chase at 37°C (Figure 4A-C). Equivalent experiments, in which cells had been fixed at different time-points of this pulse-chase regime, allowed us to confirm this through immunofluorescence and colocalization with additional markers (Figure. S2 A-C). During the accumulation phase at 19.5°C, Shiga toxin colocalized with the endosomal markers SNX1 (sorting nexin 1) and TFRC (Figure. S2 A, C). After 30 min of chase, Shiga toxin in control cells colocalized almost completely with the Golgi marker beta-1,4-galactosyltransferase (B4GALT1), whereas more than 50% of Shiga toxin had remained outside the Golgi in WIPI1 KO cells (Figure. S2 B-C). This fraction of Shiga toxin had not been rerouted to late endosomes or lysosomes, because it showed virtually no colocalization with LAMP1 (Figure. S2 B-C).
Figure 4.

WIPI1 promotes transfer of STxB from early/recycling endosomes to the Golgi. (A) Confocal microscopy of living HK2 cells. Alexa Fluor 488 TF and Cy3-StxB were bound to control and WIPI1 KO cells for 30 min on ice, internalized by incubating cells at 19.5°C for 45 min (LOAD), and finally chased to the Golgi by shifting cells to 37°C for 0–30 min. Scale bars: 10 μm. (B) Quantification of Golgi localized STxB in images from (A). The ratio of average Golgi-associated fluorescence over the average total cell-associated fluorescence is represented as a function of incubation time at 37°C. Data are means ±s.d. from 3 independent experiments. Number of cells quantified: Control = 250; WIPI1 KO = 245 (C) Colocalization of TF and STxB was quantified in images from (A) at different time points after the shift to 37°C. Values are the mean ± s.d. from 3 independent experiments. Number of cells quantified: Control = 240; WIPI1 KO = 220

WIPI1 promotes transfer of STxB from early/recycling endosomes to the Golgi. (A) Confocal microscopy of living HK2 cells. Alexa Fluor 488 TF and Cy3-StxB were bound to control and WIPI1 KO cells for 30 min on ice, internalized by incubating cells at 19.5°C for 45 min (LOAD), and finally chased to the Golgi by shifting cells to 37°C for 0–30 min. Scale bars: 10 μm. (B) Quantification of Golgi localized STxB in images from (A). The ratio of average Golgi-associated fluorescence over the average total cell-associated fluorescence is represented as a function of incubation time at 37°C. Data are means ±s.d. from 3 independent experiments. Number of cells quantified: Control = 250; WIPI1 KO = 245 (C) Colocalization of TF and STxB was quantified in images from (A) at different time points after the shift to 37°C. Values are the mean ± s.d. from 3 independent experiments. Number of cells quantified: Control = 240; WIPI1 KO = 220 We analyzed the impact of WIPI1 on cargo transfer from early endosomes to degradative compartments through EGFR. Cells were serum-starved for 24 h, stimulated with EGF and analyzed by immunofluorescence. 15 min after EGF addition, more than 80% of EGFR-positive structures colocalized with the early endosomal marker EEA1 in control cells (Figure 5A,B). Between 30 and 60 min, colocalization with EEA1 gradually decreased, whereas the overlap of EGFR with LAMP1-positive structures increased, indicating the arrival of EGFR at degradative compartments. In WIPI1 KO cells, EGFR reached early endosomes similarly as in control cells within 15 min, but it stayed there and did not colocalize with LAMP1 at later time points. These results were confirmed by western blot analysis. Whereas control cells degraded 80% of EGFR within 60 min after EGF addition, WIPI1 KO cells could not degrade EGFR (Figure 5C-D). Stabilization of EGFR is probably not due to reduced proteolytic capacity of the late endosomal/lysosomal compartments. This is suggested by control experiments with lysotracker, which probes the acidification that is crucial for full proteolytic activity of lysosomes, and with BZiPAR, a probe for lysosomal protease activity in living cells [69]. Staining with LysoTracker and BZiPAR did not reveal significant differences between WIPI1 KO and control cells (Figure. S3 A, B), but the BZiPAR signal was absent when lysosomal hydrolase activity was quenched by the protease inhibitor chymostatin. This suggests that also the transfer of EGFR from early/sorting endosomes to degradative compartments requires WIPI1. WIPI1 is hence involved in multiple protein exit pathways from endosomes.
Figure 5.

EGFR remains in early endosomes of WIPI1 KO cells and is protected against degradation. (A) CTR and WIPI1 KO cells were serum-starved for 24 h and then supplemented with EGF (100 ng/ml). After the indicated times, cells were fixed, permeabilized, DAPI-labeled (blue) and decorated with antibodies to EGFR (red), EEA1 or LAMP1 (green). Scale bar: 10 μm. Insets show enlargements of the outlined areas. (B) Quantification data from (A). Colocalization of EGFR-EEA1 or EGFR-LAMP1 over time. Manders’ correlation is shown. Values are the mean ± s.d.; (n = 3 independent experiments). Number of cells quantified: CTR = 180; WIPI1 KO = 180. (C) EGFR degradation. CTR and WIPI1 KO cells were stimulated with EGF for different periods of time, lysed and subjected to SDS-PAGE and western analysis for EGFR. ACTB/β-actin served as a loading control. (D) Quantification of EGFR from (C), using the value at time 0 (cells starved for 24 h) as 100% reference. Data are means ±s.d., from three independent experiments

EGFR remains in early endosomes of WIPI1 KO cells and is protected against degradation. (A) CTR and WIPI1 KO cells were serum-starved for 24 h and then supplemented with EGF (100 ng/ml). After the indicated times, cells were fixed, permeabilized, DAPI-labeled (blue) and decorated with antibodies to EGFR (red), EEA1 or LAMP1 (green). Scale bar: 10 μm. Insets show enlargements of the outlined areas. (B) Quantification data from (A). Colocalization of EGFR-EEA1 or EGFR-LAMP1 over time. Manders’ correlation is shown. Values are the mean ± s.d.; (n = 3 independent experiments). Number of cells quantified: CTR = 180; WIPI1 KO = 180. (C) EGFR degradation. CTR and WIPI1 KO cells were stimulated with EGF for different periods of time, lysed and subjected to SDS-PAGE and western analysis for EGFR. ACTB/β-actin served as a loading control. (D) Quantification of EGFR from (C), using the value at time 0 (cells starved for 24 h) as 100% reference. Data are means ±s.d., from three independent experiments

The amphipathic α-helix of WIPI1 is required for formation and fission of endosomal tubules

Protein traffic along the above-mentioned pathways from endosomes to other membranes is mediated by tubulo-vesicular carriers. A defect in these trafficking routes might result from failure to form the carriers, to recruit cargo into them, to transport them or to fuse them with their target compartment. We hence dissected which subreaction is affected by inactivation of WIPI1. Our previous studies had shown that the purified yeast PROPPIN Atg18 can tubulate and fission giant unilamellar liposomes [55]. However, WIPI1 could promote protein exit pathways in other ways (as exemplified through its role in the autophagic pathway, see below), so this is not a given. Therefore, we analyzed whether critical features for liposome fission activity of Atg18 are necessary for the functioning of WIPI1 in endosomal morphology and trafficking in mammalian cells. These include the two lipid binding sites of the protein, its capacity to bind PtdIns(3,5)P2, and the membrane-triggered formation of an amphipathic α-helix, which must insert into the bilayer to deform and fission it. The role of the amphipathic helix was tested by swapping two pairs of hydrophobic/hydrophilic amino acids on opposite sides of the helix. This generates a scrambled loop of reduced amphipathic character but of identical size and amino acid composition as in the wild-type protein (EGFP-WIPI1[Sloop]; Figure 6A,B). We also designed a variant lacking a significant part of this hydrophobic loop (aa 272–290; EGFP-WIPI1[ΔLoop]; Figure 6B), and a double arginine-to-alanine substitution in the FRRG motif of the lipid binding sites, which completely abolishes phosphoinositide binding by WIPI1 (EGFP-WIPI1[FAAG]). These three variants and a wildtype version of WIPI1 were expressed in control and WIPI1 KO cells at comparable levels, as shown by western blot (Figure. S4 A, B). Fluorescence microscopy revealed that cells transfected with EGFP-WIPI1[Sloop] present extremely long tubular fluorescent structures, which emanate from enlarged globular structures in the perinuclear area and extended into the periphery of the cells (Figure 6C,D). These tubules were produced only when EGFP-WIPI1[Sloop] was expressed on top of the endogenous wildtype alleles, but not upon expression of EGFP-WIPI1[Sloop] in WIPI1 KO cells. Expression of EGFP-WIPI1[ΔLoop] did not show any tubular structures in either background. EGFP-WIPI1[ΔLoop] was recruited to the membranes similarly as WIPI1, indicating that the amphipathic helix is not essential for membrane binding in vivo (Figure 6C). EGFP-WIPI1[FAAG], in agreement with previous studies [27,63,65], did not show any membrane association and did not induce tubules (Figure 6C,D). That tubule formation requires the simultaneous presence of EGFP-WIPI1[Sloop] and of the endogenous wild-type protein suggests that the formation of tubules is a cooperative activity of multiple WIPI1 molecules, at least a fraction of which must carry the amphipathic helix with a sufficient hydrophobic moment.
Figure 6.

Role of the amphipathic α-helix in blade 6 of WIPI1. (A) Schematic depiction of WIPI1, showing its 7-bladed ß-propeller, the two phosphoinositide binding sites and the hydrophobic CD-loop on blade 6 that folds into an amphipathic helix when in contact with a bilayer [55]. Helical wheel projections show the CD-loop on blade 6 of WIPI1 and WIPI1[Sloop]. Colored arrows indicate the two pairs of amino acids that have been swapped. The magnitude and direction of the hydrophobic moment of the helices was predicted using the online tool Heliquest [118]. It is indicated by the vector in the center of the wheels. (B) Sequences of the hydrophobic loop regions of WIPI1, WIPI1[Sloop] and WIPI1[ΔLoop]. The amino acids removed in WIPI1[ΔLoop] were EEPSTWSGYMGKMFMAATNYL, which comprises the entire sequence shown in the helical wheels. Predicted α-helices analyzed in (A) are plotted in red. The two pairs of hydrophobic/hydrophilic amino acids swapped in WIPI1[Sloop] are highlighted by rectangles. (C) Representative images of CTR and WIPI1 KO cells expressing EGFP-tagged wild-type or the indicated mutant forms of WIPI1. Pictures were taken 18 h after transfection. Tubules are marked by arrows. Scale bar: 10 μm. (D) Quantification of control and WIPI1 KO cells showing tubules after expressing different WIPI1 plasmids for 18 h. The data are mean values ±s.d.; n = 3 independent experiments (20 transfected cells were analyzed per plasmid per experiment in both CTR and WIPI1 KO cells)

Role of the amphipathic α-helix in blade 6 of WIPI1. (A) Schematic depiction of WIPI1, showing its 7-bladed ß-propeller, the two phosphoinositide binding sites and the hydrophobic CD-loop on blade 6 that folds into an amphipathic helix when in contact with a bilayer [55]. Helical wheel projections show the CD-loop on blade 6 of WIPI1 and WIPI1[Sloop]. Colored arrows indicate the two pairs of amino acids that have been swapped. The magnitude and direction of the hydrophobic moment of the helices was predicted using the online tool Heliquest [118]. It is indicated by the vector in the center of the wheels. (B) Sequences of the hydrophobic loop regions of WIPI1, WIPI1[Sloop] and WIPI1[ΔLoop]. The amino acids removed in WIPI1[ΔLoop] were EEPSTWSGYMGKMFMAATNYL, which comprises the entire sequence shown in the helical wheels. Predicted α-helices analyzed in (A) are plotted in red. The two pairs of hydrophobic/hydrophilic amino acids swapped in WIPI1[Sloop] are highlighted by rectangles. (C) Representative images of CTR and WIPI1 KO cells expressing EGFP-tagged wild-type or the indicated mutant forms of WIPI1. Pictures were taken 18 h after transfection. Tubules are marked by arrows. Scale bar: 10 μm. (D) Quantification of control and WIPI1 KO cells showing tubules after expressing different WIPI1 plasmids for 18 h. The data are mean values ±s.d.; n = 3 independent experiments (20 transfected cells were analyzed per plasmid per experiment in both CTR and WIPI1 KO cells)

WIPI1 tubules stem from a variety of endosomal subtypes

Endosomes form tubular structures, which can give rise to transport carriers that shuttle proteins between these compartments [39,70]. We hence tested the long tubules provoked by WIPI1[Sloop] for the presence of endosomal RAB-GTPases as marker proteins for their origin [71,72]. We co-expressed EGFP-WIPI1[Sloop] with a panel of RAB-GTPases carrying various N-terminal fluorescent protein tags (Figure 7A). The tubules were mostly marked by RAB5, RAB4 and RAB11, markers for early and recycling endosomes, which showed colocalization of 38%, 88% and 76% respectively. Much less colocalization was observed with RAB7 (17%) and RAB9 (4%), markers for late endosomes and lysosomes (Figure 7B). The association of tubules with early and recycling endosomes was confirmed by the enrichment of further markers on them: 58% colocalization with TFRC; 66% with the sorting nexin SNX1; and 52% with the sorting nexin SNX6. By contrast, we found very low colocalization with the late-endosomal marker LAMP1 (15%) and with a subunit of the retriever complex, VPS35L/C16orf62 (6%) (Figure 7C,D). We also observed colocalization between WIPI1[Sloop] and lipids that are enriched in endosomal compartments, as indicated by EGFP-FYVE2 (Figure 8A), a probe with specificity to PtdIns3P [73]. mCherry–ML1N2, a bona fide PtdIns(3,5)P2-labeling probe [74], was mainly enriched on the large, globular structures marked by EGFP-WIPI1[Sloop] in the perinuclear area. On the tubules, it was much less present than EGFP-FYVE2 (Figure 8B,C). These results are consistent with the view that WIPI1-associated tubules originate mainly from early and recycling endosomes.
Figure 7.

WIPI1[Sloop] is preferentially associated with recycling endosomes. (A) Colocalization with RAB proteins. Live cell images of HK2 cells expressing EGFP-WIPI1[Sloop], mCherry-RAB5, RFP-RAB4, mCherry-RAB7 proteins, DsRed-RAB9 or DsRed-RAB11. Scale bars: 10 μm. Insets show enlargements of the outlined areas. (B) Quantification. Colocalization between WIPI1[Sloop] and different RAB proteins on the tubular structures was assessed using the Manders’ colocalization coefficient M2, calculated in ImageJ. Data are means ±s.d. of n = 150 cells, from three independent experiments. (C) Colocalization with other endo-lysosomal marker proteins. Cells were fixed 18 h after transfection with EGFP-WIPI1[Sloop], stained with the indicated antibodies and imaged by confocal microscopy. Insets show enlargements of the outlined areas. Scale bars: 10 μm. (D) Quantitative colocalization analysis of the images from (C) was carried out for the tubular structures as in (B). Data are means ± s.d. of n = 160 cells from three independent experiments

Figure 8.

WIPI1-associated tubules labeled with probes for PtdIns3P and PtdIns(3,5)P2. HK2 cells expressing (A) EGFP-FYVE2 and mCherry-WIPI1[Sloop], or (B) EGFP-WIPI1[Sloop] and mCherry-ML1N2 were fixed and imaged. Scale bars: 10 μm. The outlined areas are shown at higher magnification. (C) Quantitative colocalization analysis in the entire cell or for the tubular structures was carried out using ImageJ and the pictures from (A) and (B). Data are means ±s.d. of n = 150 cells pooled from three independent experiments

WIPI1[Sloop] is preferentially associated with recycling endosomes. (A) Colocalization with RAB proteins. Live cell images of HK2 cells expressing EGFP-WIPI1[Sloop], mCherry-RAB5, RFP-RAB4, mCherry-RAB7 proteins, DsRed-RAB9 or DsRed-RAB11. Scale bars: 10 μm. Insets show enlargements of the outlined areas. (B) Quantification. Colocalization between WIPI1[Sloop] and different RAB proteins on the tubular structures was assessed using the Manders’ colocalization coefficient M2, calculated in ImageJ. Data are means ±s.d. of n = 150 cells, from three independent experiments. (C) Colocalization with other endo-lysosomal marker proteins. Cells were fixed 18 h after transfection with EGFP-WIPI1[Sloop], stained with the indicated antibodies and imaged by confocal microscopy. Insets show enlargements of the outlined areas. Scale bars: 10 μm. (D) Quantitative colocalization analysis of the images from (C) was carried out for the tubular structures as in (B). Data are means ± s.d. of n = 160 cells from three independent experiments WIPI1-associated tubules labeled with probes for PtdIns3P and PtdIns(3,5)P2. HK2 cells expressing (A) EGFP-FYVE2 and mCherry-WIPI1[Sloop], or (B) EGFP-WIPI1[Sloop] and mCherry-ML1N2 were fixed and imaged. Scale bars: 10 μm. The outlined areas are shown at higher magnification. (C) Quantitative colocalization analysis in the entire cell or for the tubular structures was carried out using ImageJ and the pictures from (A) and (B). Data are means ±s.d. of n = 150 cells pooled from three independent experiments

WIPI1-covered tubules carry cargo and are connected to endosomes

The long tubular structures protrude from regions containing enlarged endosomal compartments. We used fluorescence recovery after photobleaching (FRAP) to distinguish whether they are only in the vicinity of these compartments, in which case their membranes should be separated, or whether they actually emanate from them, in which case proteins should move between them. In HK2 cells transiently expressing EGFP-WIPI1[Sloop], tubules were photo-bleached and the recovery of the GFP signal was monitored by confocal microscopy. The tubular structures recovered 40% of the initial fluorescence already within 10 s after bleaching (Figure 9A,B). Fluorescently tagged RAB5, RAB4 and RAB11 proteins on them showed similar recovery, although at a slightly lower rate (Figure 9C-H). Fluorescence recovery along these tubular structures started close to the larger organelle that the tubule was attached to and proceeded from there toward the tip of the tubule (Figure 9C,E,G). This directional recovery suggests that fluorescent proteins repopulate the tubule through diffusion from the larger organelle rather than by direct membrane attachment from a cytosolic pool. Within or next to a tubule, we often found small punctate structures that strongly concentrated TF. A photodepletion approach confirmed that also those structures were connected to the tubules to which they localized, because they exchanged EGFP-WIPI1 with these tubules (Figure 10A,B). These dots might be parts of endosomal compartments that have been pulled out of a larger organelle without separating from it. The tubules thus show properties that we expect from exaggerated forms of endosomal transport carriers that cannot detach from their compartment due to a block in membrane fission.
Figure 9.

WIPI1-tubules are continuous with endosomes. (A) In HK2 cells expressing EGFP-WIPI1[Sloop], EGFP-labeled tubules (in the boxed area) were photobleached. EGFP fluorescence is shown before and at different times after bleaching. The dashed line indicates the bleached region. The boxed area is shown at higher magnification. Scale bar: 10 μm (B) Quantification of experiments as in a. Means ± s.d. are shown. Data are representative of 3 independent experiments with at least 20 cells analyzed in each experiment. C-H. Experiments as in (A) and (B), respectively, but with cells expressing EGFP-WIPI1[Sloop] plus (C, D) RFP-RAB4, (E, F) DsRed-RAB11 and (G, H) mCherry-RAB5

Figure 10.

TF-enriched structures on WIPI1 tubules. (A) Photodepletion. HK2 cells were transfected with EGFP-WIPI1[Sloop]. After 18 h, they were loaded with Alexa Fluor 568-TF as in Figure 2 C. A region on a tubule (white dotted circle) was photobleached using a 488-nm laser. The images show concomitant photodepletion of EGFP-fluorescence from a TF-enriched punctate structure, which is outside the bleached area and associated with an EGFP-WIPI1[Sloop]-positive tubule. Two cycles of photodepletion and recovery were recorded. The boxed area of the cell in the image on the left is shown at higher magnification. Scale bar: 10 μm (B) Quantification of experiments as in (a). EGFP-fluorescence intensity was measured over time for EGFP-WIPI1[Sloop]-positive dots localized on a tubule (magenta circle in A), or far away from the tubule (light blue circle in A). Means ±s.d. are shown. 3 independent experiments with 10 cells each were analyzed

WIPI1-tubules are continuous with endosomes. (A) In HK2 cells expressing EGFP-WIPI1[Sloop], EGFP-labeled tubules (in the boxed area) were photobleached. EGFP fluorescence is shown before and at different times after bleaching. The dashed line indicates the bleached region. The boxed area is shown at higher magnification. Scale bar: 10 μm (B) Quantification of experiments as in a. Means ± s.d. are shown. Data are representative of 3 independent experiments with at least 20 cells analyzed in each experiment. C-H. Experiments as in (A) and (B), respectively, but with cells expressing EGFP-WIPI1[Sloop] plus (C, D) RFP-RAB4, (E, F) DsRed-RAB11 and (G, H) mCherry-RAB5 TF-enriched structures on WIPI1 tubules. (A) Photodepletion. HK2 cells were transfected with EGFP-WIPI1[Sloop]. After 18 h, they were loaded with Alexa Fluor 568-TF as in Figure 2 C. A region on a tubule (white dotted circle) was photobleached using a 488-nm laser. The images show concomitant photodepletion of EGFP-fluorescence from a TF-enriched punctate structure, which is outside the bleached area and associated with an EGFP-WIPI1[Sloop]-positive tubule. Two cycles of photodepletion and recovery were recorded. The boxed area of the cell in the image on the left is shown at higher magnification. Scale bar: 10 μm (B) Quantification of experiments as in (a). EGFP-fluorescence intensity was measured over time for EGFP-WIPI1[Sloop]-positive dots localized on a tubule (magenta circle in A), or far away from the tubule (light blue circle in A). Means ±s.d. are shown. 3 independent experiments with 10 cells each were analyzed

PtdIns3P and PtdIns(3,5)P2 are required for different WIPI1 activities

Both PtdIns3P and PtdIns(3,5)P2 are required for membrane recycling events on endosomes. PtdIns(3,5)P2 was proposed to support the fission of endosomal transport carriers [7,59,73,75], but the responsible effector proteins have not yet been identified. We first verified the effects of the PtdIns-3-kinase inhibitor wortmannin and of the PtdIns3P-5-kinase (PIKfyve) inhibitor YM201636 in our cell lines. Block of PtdIns(3,5)P2 production by YM201636 allowed the association of EGFP-WIPI1 with the membranes to persist (Figure. S5). It induced the accumulation of short tubular structures in cells expressing EGFP-WIPI1. In cells expressing EGFP-WIPI1[Sloop], YM201636 further increased the length and the number of the existing tubules. However, it did not induce any tubular structures in cells expressing EGFP-WIPI1[ΔLoop], nor in cells expressing EGFP-WIPI1[FAAG], suggesting that WIPI1 is required for forming the tubules. Wortmannin, which abrogates synthesis of both PtdIns3P and PtdIns(3,5)P2, led to a rapid loss of WIPI1 membrane localization in the cells (Figure. S5) [12,65]. Therefore, we used RFP-RAB4 as alternative marker, since it efficiently marks WIPI1-dependent tubules, as shown above. Wortmannin prevented formation of the tubules that are normally seen in EGFP-WIPI1[Sloop] cells (Figure. S5C). This suggests that PtdIns3P is needed for the generation of WIPI1-dependent tubules. PtdIns(3,5)P2 is dispensable for tubule formation but absence of this lipid provokes their accumulation in an exaggerated, elongated form.

WIPI1 fission activity requires its lipid binding site II

We tested the hypothesis that tubule formation requires WIPI1 and PtdIns3P, whereas WIPI1 in conjunction with PtdIns(3,5)P2 may counteract the accumulation of tubules by supporting their fission. If the two phosphoinositides promote different activities through the same effector protein, substitutions in the two lipid binding sites might differentiate these effector functions. We sought such substitutions by mutating the two lipid binding sites of WIPI1 individually. Work on the yeast PROPPIN Hsv2, a homolog of WIPI1, had suggested that site I preferentially binds PtdIns3P, whereas site II prefers PtdIns(3,5)P2 [23]. The study identified substitutions of conserved residues with differential effects on lipid binding: H179 (site I) impaired binding to PtdIns3P but not to PtdIns(3,5)P2, whereas substitution of H249 (site II) eliminated binding to PtdIns(3,5)P2 and reduced binding to PtdIns3P. These substitutions might hence allow to discriminate between PtdIns3P and PtdIns(3,5)P2-dependent activities. We substituted the two corresponding histidines in WIPI1 (Figure. S6 A) and expressed the following proteins in control and WIPI1 KO cells: WIPI1H185N and WIPI1H185A (affecting site I), and WIPI1H257Q and WIPI1H257A (affecting site II). As negative controls, we substituted single arginines in the FRRG motif (WIPI1R226A and WIPI1R227A), which simultaneously affect both binding sites and strongly reduce membrane association 10,23,63,76. Whereas EGFP-WIPI1R226A and EGFP-WIPI1R227A remained in the cytosol as expected (Figure. S6 B), the proteins with substitutions in site I (WIPI1H185A) and site II (WIPI1H257A) did associate with the membranes. Both substituted proteins showed an increased cytosolic background compared to the wildtype constructs, suggesting reduced affinity for the membrane (Figure. S6 B). This was confirmed by differential centrifugation of extracts from these cells, in which over 80% of the substituted EGFP-WIPI1 remained in the cytosolic supernatant (Figure. S6 C), whereas EGFP-WIPI1 fractionated entirely with the membranes. In order to circumvent potential effects due to lower membrane binding of WIPI1, we added a prenyl anchor to the C-terminus of WIPI1. Prenyl anchors are used by cells to increase the affinity of a great variety of proteins for membranes. We thus created the corresponding mutants carrying a 15-glycine spacer plus a CVVM motif for prenylation (Figure 11A). The CVVM motif allowed all WIPI1 mutants to be recruited to the membranes as efficiently as the wildtype protein, as judged by microscopy and subcellular fractionation (Figure 11B,C). The endosomal, WIPI1-associated compartments showed strong morphological differences: Substitutions R226A and R227A in the FRRG motif led to fewer and larger compartments, whereas the site I substitution H185A showed little effect. The site II substitution H257A led to an enormous enlargement of the endosomal compartments and to the formation of long tubular structures (Figure 11B, S6 B), which is consistent with perturbed membrane exit from these compartments. Overall, the site II substitution H257A phenocopied the morphological effects of manipulations interfering with fission activity, such as inhibition of PtdIns(3,5)P2 synthesis (Figure. S5) or eliminating the amphipathic character of the hydrophobic loop (Figure 6C). This suggests that PtdIns(3,5)P2 promotes fission through lipid binding site II of WIPI1.
Figure 11.

WIPI1 fission activity requires its lipid binding site II. (A) Sequences of WIPI1 and WIPI1[15gly-CVVM] were aligned with the Clustal Omega program. The added prenylation sequence and its spacer are plotted in red. (B) Endosome morphologies. CTR and WIPI1 KO cells were transfected with EGFP-WIPI1[15gly-CVVM] carrying the indicated substitutions and analyzed by live confocal microscopy. Scale bar: 10 μm. (C) Expression levels. CTR cells from (B) were lysed, fractionated by centrifugation into membrane and cytosolic supernatant and subjected to SDS-PAGE and western blotting against WIPI1 and TUBA/α-tubulin as loading control. The quantified signals are displayed as the ratio of the transfected WIPI1 over TUBA as a loading control. All ratios were normalized to that for WIPI1[15gly-CVVM], which had been set to 1. Means ±s.d. are shown; n = 3 independent experiments

WIPI1 fission activity requires its lipid binding site II. (A) Sequences of WIPI1 and WIPI1[15gly-CVVM] were aligned with the Clustal Omega program. The added prenylation sequence and its spacer are plotted in red. (B) Endosome morphologies. CTR and WIPI1 KO cells were transfected with EGFP-WIPI1[15gly-CVVM] carrying the indicated substitutions and analyzed by live confocal microscopy. Scale bar: 10 μm. (C) Expression levels. CTR cells from (B) were lysed, fractionated by centrifugation into membrane and cytosolic supernatant and subjected to SDS-PAGE and western blotting against WIPI1 and TUBA/α-tubulin as loading control. The quantified signals are displayed as the ratio of the transfected WIPI1 over TUBA as a loading control. All ratios were normalized to that for WIPI1[15gly-CVVM], which had been set to 1. Means ±s.d. are shown; n = 3 independent experiments Next, we tested whether the WIPI1 versions leading to the accumulation of endosomal tubules (WIPI1[Sloop] and WIPI1H257A[15gly-CVVM]) showed corresponding defects in the recycling of endocytic cargoes and in the sorting from early endosomes to degradative compartments. We used TF and EGFR as model proteins in pulse-chase assays as described above. WIPI1 KO cells transfected with a plasmid expressing EGFP-WIPI1 recovered their TF-recycling and their EGFR degradation (Figure 12). By contrast, EGFP-WIPI1[Sloop] and EGFP-WIPI1H257A[15gly-CVVM] not only failed to induce any rescue in WIPI1 KO cells, but they even exerted a dominant-negative effect on the trafficking of both model proteins, when they were expressed on top of endogenous WIPI1.
Figure 12.

Effect of WIPI1 mutants accumulating endosomal tubules on protein exit from endosomes. (A) TF recycling. Control and WIPI1 KO cells were transfected with EGFP-WIPI1, EGFP-WIPI1[Sloop] or EGFP-WIPI1H257A[15gly-CVVM] for 18 h. Then, they were serum-starved for 60 min, loaded with Alexa Fluor568-conjugated TF and chased at 37°C as in Figure 2 C. Scale bar: 10 μm. The white dashed lines indicate the circumference of the cells. TF-fluorescence was quantified as in Figure. 2B. Mean values ± s.d. are shown. n = 3 independent experiments with a total of 210 cells analyzed per condition. (B) EGFR degradation. CTR and WIPI1 KO cells expressing EGFP-WIPI1, EGFP-WIPI1[Sloop] and EGFP-WIPI1H257A[15gly-CVVM] as in (A) were serum-starved for 24 h and then stimulated with EGF (100 ng/ml) for 60 min. Cells were fixed, permeabilized, and stained with antibody to EGFR (red). Scale bar: 10 μm. EGFR-fluorescence was quantified as in Figure. 2B. 180 cells per condition stemming from 3 independent experiments were analyzed. Mean values ± s.d. are shown

Effect of WIPI1 mutants accumulating endosomal tubules on protein exit from endosomes. (A) TF recycling. Control and WIPI1 KO cells were transfected with EGFP-WIPI1, EGFP-WIPI1[Sloop] or EGFP-WIPI1H257A[15gly-CVVM] for 18 h. Then, they were serum-starved for 60 min, loaded with Alexa Fluor568-conjugated TF and chased at 37°C as in Figure 2 C. Scale bar: 10 μm. The white dashed lines indicate the circumference of the cells. TF-fluorescence was quantified as in Figure. 2B. Mean values ± s.d. are shown. n = 3 independent experiments with a total of 210 cells analyzed per condition. (B) EGFR degradation. CTR and WIPI1 KO cells expressing EGFP-WIPI1, EGFP-WIPI1[Sloop] and EGFP-WIPI1H257A[15gly-CVVM] as in (A) were serum-starved for 24 h and then stimulated with EGF (100 ng/ml) for 60 min. Cells were fixed, permeabilized, and stained with antibody to EGFR (red). Scale bar: 10 μm. EGFR-fluorescence was quantified as in Figure. 2B. 180 cells per condition stemming from 3 independent experiments were analyzed. Mean values ± s.d. are shown

WIPI1 acts in autophagosome formation and in endosomal protein exit through distinct mechanisms

Finally, we asked whether the originally identified function for WIPI proteins in autophagosome formation utilizes the same molecular features as protein exit from endosomes. We first measured the response of our HK2 cell line to 3 hours of starvation in HBSS medium (Figure. S7), using mCherry-LC3 as a marker of autophagosomes in fluorescence microscopy. Starvation triggered a 7-fold increase in the number of punctate structures labeled by mCherry-LC3. In agreement with previous observations in other cell lines [12,13,17], knockdown of WIPI2 reduced the number of puncta in starved cells by 70% (Figure. S7). Knockdown of WIPI1, which occurs with comparable efficiency as the knockdown of WIPI1 (Figure 3A,B), reduced the number of puncta in the starved cells only by 30%. We also assayed autophagy in the knockdowns through a western blot assay of the lipidation of LC3, which coincides with the formation of autophagosomes (Figure. S7 C, D) [76,77]. This modification converts the cytosolic form LC3-I into the autophagosome-associated LC3-II, which accumulates when its degradation in lysosomal compartments is suppressed by protease inhibitors. Inhibition of lysosomal protease activity was confirmed through an assay with BZiPAR (Figure. S8). The LC3-II assay showed a strong effect for the knockdown of WIPI2, but only a weak and statistically non-significant effect of the knockdown of WIPI1. This agrees with earlier WIPI1 knockdown experiments in other cell lines [13]. That WIPI1 knockdown did not lead to a significant reduction of LC3-II in the blot assay, whereas it had a robust effect in the microscopic assay with knockdowns (Figures. S7 A,B, S8) as well as well as in WIPI1 KO cells (see below) may be due to the fact that the blot is an ensemble assay, in which non-transfected cells provide an elevated background. This background of non-transfected cells is excluded in the microscopy assay and not present in a WIPI1 KO. We used WIPI1 KO cells to express the WIPI1 variants that interfere with fission activity and test their impact on autophagy. These variants include substitutions in site I or site II (EGFP-WIPI1H185A[15gly-CVVM] and EGFP-WIPI1H257A[15gly-CVVM]), the FRRG motif (EGFP-WIPI1R226A[15gly-CVVM] and EGFP-WIPI1R227A[15gly-CVVM]) and the amphipathic helix (EGFP-WIPI1[Sloop]). WIPI1 and all variants increased the formation of mCherry-LC3 puncta (Figure 13) and the formation of LC3-II (Figure 14) to a similar degree, by 50%. Therefore, the amphipathic α-helix and lipid binding site II are not essential for autophagy, whereas they are crucial for receptor exit from endosomes.
Figure 13.

WIPI1 variants hindering protein exit from endosomes promote formation of mCherry-LC3 puncta like WIPI1 (A) WIPI1 KO cells expressing mCherry-LC3 and the indicated variants of EGFP-WIPI1 were incubated in growth medium or in HBSS for 3 h and analyzed by confocal microscopy. Scale bar: 10 µm. (B) Quantification. The number of LC3-positive structures in the cells from A was counted. The red line indicates the mean; n = 150 cells per condition, pooled from three independent experiments. P-values were calculated by one-way ANOVA and t-test t (analysis performed with 99% confidence ***p < 0.0001, NS = not significant)

Figure 14.

Formation of LC3-II is not affected by WIPI1 mutations hindering protein exit from endosomes. (A) Total cell lysates of the cells from WIPI1 KO cells re-expressing the indicated WIPI1 variants (from Figure. 13 A; 50 μg of protein per sample) were analyzed by SDS–PAGE and western blotting using the indicated antibodies. TUBA/α-tubulin served as a loading control. A representative blot is shown. (B) The ratio LC3-II:LC3-I and LC3-II:TUBA/α-tubulin was quantified by a fluorescence scanner. Data are means ±s.d.; n = 3 independent experiments. P values are indicated and were calculated by t-Test. The analysis was performed with 99% confidence: *p < 0.01; NS = not significant)

WIPI1 variants hindering protein exit from endosomes promote formation of mCherry-LC3 puncta like WIPI1 (A) WIPI1 KO cells expressing mCherry-LC3 and the indicated variants of EGFP-WIPI1 were incubated in growth medium or in HBSS for 3 h and analyzed by confocal microscopy. Scale bar: 10 µm. (B) Quantification. The number of LC3-positive structures in the cells from A was counted. The red line indicates the mean; n = 150 cells per condition, pooled from three independent experiments. P-values were calculated by one-way ANOVA and t-test t (analysis performed with 99% confidence ***p < 0.0001, NS = not significant) Formation of LC3-II is not affected by WIPI1 mutations hindering protein exit from endosomes. (A) Total cell lysates of the cells from WIPI1 KO cells re-expressing the indicated WIPI1 variants (from Figure. 13 A; 50 μg of protein per sample) were analyzed by SDS–PAGE and western blotting using the indicated antibodies. TUBA/α-tubulin served as a loading control. A representative blot is shown. (B) The ratio LC3-II:LC3-I and LC3-II:TUBA/α-tubulin was quantified by a fluorescence scanner. Data are means ±s.d.; n = 3 independent experiments. P values are indicated and were calculated by t-Test. The analysis was performed with 99% confidence: *p < 0.01; NS = not significant) By integrating our observations with the known property of the WIPI1 homolog Atg18 to undergo PtdIns(3,5)P2-dependent oligomerization [55,78], we can formulate a working model of WIPI1 function on endo-lysosomal compartments. We propose that WIPI1 in conjunction with PtdIns3P promotes the formation of tubular endosomal transport carriers. This activity requires lipid binding site I, but not PtdIns(3,5)P2. Lipid binding site II and PtdIns(3,5)P2 become important to induce the fission activity of the protein, which depends on the insertion of its amphipathic helix into the membrane. PtdIns(3,5)P2-dependent oligomerization should facilitate fission by locally concentrates these membrane-inserting helices [79]. The role of WIPI1 in autophagy is independent of these fission-related features. Here, the protein exploits its affinity for PtdIns3P, probably in a templating function that recruits other factors to the phagophore, similarly as shown for the WIPI1 homologs Atg18 and WIPI2 [13,16,17,80-82].

Discussion

While the coat proteins involved in the formation of tubulo-vesicular endosomal transport carriers become increasingly well understood [39,70], it is still unclear how these carriers are detached from the donor organelle. In contrast to previous suggestions that, in starving cells, the autophagic machinery promotes endosomal trafficking by autophagic removal of damaged endosomes [30], our observations present evidence for a direct function of specifically WIPI1 in both the formation and fission of these tubules in living mammalian cells. They permit to separate these two functions through their differential requirements for PtdIns3P, PtdIns(3,5)P2 and the two WIPI1 lipid binding sites. They underscore that the two lipid binding sites modify the function of the protein and do not merely serve as membrane anchors. We propose that formation and release of the carriers depend on the membrane-insertion of the amphipathic helix on CD-loop 6 of WIPI1. It is notable that several substitutions in WIPI1, which were identified in melanoma or pancreatic cancer cells [11], map to this loop. This provides a hint on the nature of the underlying cellular defect, because the amphipathic helix is only required for the membrane fission activity of WIPI1, but not for autophagy. Our results hence suggest that the substitutions promote these cancers through perturbation of cellular signaling at the level of the endosome. In support of this argument, we show that inactivation of WIPI1 hinders the degradation of EGFR and leads to an accumulation of the protein in the endo-lysosomal system, from where it can actually continue to signal [83]. Since EGFR activity is necessary for the growth of melanomas and EGFR overactivation can even induce it [84-86], we propose that WIPI1 mutations contribute to these cancers through excessive signaling of accumulated endosomal EGFR and/or other growth factor receptors [87]. This hypothesis will be tested in future studies. Our observations suggest that WIPI1 acts cooperatively on endosomal membranes in vivo, providing a first indication that oligomerization, which can observed with the purified WIPI1 homolog Atg18 in vitro [55,78], is functionally relevant. Oligomerization can support fission by enhancing the induction of curvature by inserted amphipathic helices [88,89]. Previous studies suggested an involvement of the dynamin-like GTPase Vps1 in the fission of retrograde transport carriers in yeast [90,91]. Yeast Atg18 promotes retrograde trafficking in a so far undefined manner [10]. Its homology to WIPI1 render it very likely that it also promotes fission of transport carriers in this pathway. Then, the formation of these carriers shows remarkable similarity to the fission of yeast vacuoles into smaller vesicles, which also requires both Atg18 and Vps1 [10,55,56,92-96]. For exit from mammalian endosomes, a role of a dynamin-related GTPase has not been firmly established. However, the EHD proteins, which are present on endosomes, share some properties with dynamin-related GTPases and show membrane fission activity in vitro [97-102]. Like dynamin-related GTPases, the EHD proteins self-interact, hydrolyze nucleotides and are potential mechanochemical devices to deform or constrict membrane tubules. This leads us to the working model that membrane fission at endo-lysosomal compartments may generally require a PROPPIN and a mechanochemical nucleoside triphosphatase. They may need to cooperate to first gradually constrain the diameter of a membrane tubule and then sever it. We envision a situation similar to endocytosis, where mechanochemical dynamin-related GTPases collaborate with membrane-bending BAR-domain proteins such as SH3GL/endophilin and AMPH (amphiphysin) to facilitate fission. Depending on the type of endocytic vesicle formed, dynamin is not strictly required and it can be replaced by other mechanical stresses, mediated e.g. through the cytoskeleton and motor proteins [53,103-106]. In the formation of endosomal transport carriers, additional mechanical stress can be provided by the actin-cytoskeleton and the WASH complex [42-44,107]. Therefore, we now undertake systematic analyses of the interactions of PROPPINs with other factors involved in protein exit from endosomes. Protein sorting from endosomes requires both PtdIns(3,5)P2 and PtdIns3P [61]. Whereas coat complexes such as the retromer, retriever and commander [39,40,108] utilize PtdIns3P in order to bind the membrane, a requirement for PtdIns(3,5)P2 in their functioning has not been reported and the effector for PtdIns(3,5)P2 in protein exit from endosomes has remained unknown. WIPI1 and other PROPPINs are good candidates because of their affinities for both PtdIns3P and PtdIns(3,5)P2 [10,13,23-25,27,65,109]. Our data support WIPI1 as effector of PtdIns(3,5)P2, because substitutions in its lipid binding site II phenocopy the effect of an inhibition of PtdIns(3,5)P2 synthesis. Both manipulations provoke the accumulation of micrometer-long endosomal membrane tubules, suggesting that the PtdIns3P-dependent tubulation of endosomes continues while the PtdIns(3,5)P2-dependent fission of these structures is impaired. When both lipid binding sites are ablated or PtdIns3P formation is inhibited, also tubule formation is blocked. Since both tubulation and fission require WIPI1, but differ in their need for PtdIns3P, PtdIns(3,5)P2 and the second lipid binding site of WIPI1, we propose that the activities of the protein in the formation and fission of carrier vesicles are switched by the phosphoinositides that it binds. Studies with synthetic liposomes yielded differing results with respect to the specificities of the two lipid binding sites of PROPPINs. Whereas both binding sites interact with PtdIns3P, a moderate preference for PtdIns(3,5)P2 was assigned either to binding site I or II [23-25,57]. Whether this reflects a genuine functional distinction among PROPPIN family members cannot yet be judged, because these studies used different experimental conditions and different PROPPINs. However, the fact that all binding studies have revealed only moderate preferences of the two binding sites for PtdIns3P or PtdIns(3,5)P2 allows two interpretations, which are not mutually exclusive: First, PROPPINs might simply not differentiate between the two phosphoinositides. This hypothesis is inconsistent with the fact that WIPI1 substitutions in two different regions of the protein (the amphipathic helix and lipid binding site II) phenocopy the suppression of PtdIns(3,5)P2 synthesis but not PtdIns3P-dependent functions, such as formation of endosomal tubules and autophagosomes. As a second possibility, the two phosphoinositides might be differentiated through their agonist properties rather than their binding affinity and membrane recruitment. This concept is well established for receptor proteins, where numerous examples have shown that while a variety of ligands may bind a receptor with similar affinities, their agonist properties, i.e. their capacity to change the activity and conformation of the receptor, can grossly differ [110]. Therefore, we took a functional in vivo approach rather than a study of binding affinities to analyze the roles of the lipid binding sites of WIPI1. We substituted a conserved histidine, which is placed at an equivalent location in both lipid binding sites [23,25]. In contrast to the commonly used substitutions in the FRRG motif, which simultaneously affect both lipid binding sites, each of these histidines coordinates a phosphoinositide head group in only a single binding site. Since a point mutation in lipid binding site II entails the same accumulation of endosomal tubules as the ablation of fission through depletion of PtdIns(3,5)P2 or scrambling the hydrophobic loop, fission activity and the effect of PtdIns(3,5)P2 in protein exit from endosomes can be tentatively assigned to site II. This suggests a functional differentiation between the two lipid binding sites in vivo. Several observations further support the notion that the two lipid binding sites of PROPPINs are not simple membrane anchors but activate specific effector functions. First, when WIPI1 lipid binding sites are compromised or when PtdIns(3,5)P2 synthesis is inhibited, normal membrane recruitment is rescued through addition of a prenyl anchor. This restores the function of the protein in autophagy, but not in endosomal protein exit. Second, PtdIns3P suffices for the WIPI1-dependent formation of endosomal tubules, but PtdIns(3,5)P2 and lipid binding site II are required for fission. Since PtdIns(3,5)P2 is bound in a pocket of the protein, the only conceivable way how it could trigger this specific endosomal effector function is through a conformational change of the protein. Our results thus suggest that PROPPINs have two fundamentally different functional faces. We propose a working model in which PtdIns3P allows WIPI1 to support the tubulation of the endosomal membrane. PtdIns(3,5)P2 triggers WIPI1 to insert its amphiphilic helix, oligomerize and cooperatively fission the membrane during protein exit form endosomes. In autophagy, this latter feature is not utilized. The protein relies on its membrane attachment through PtdIns3P and may serve as an interaction platform for other proteins that build and expand the phagophore membrane. Different lipids bound to a PROPPIN may thus activate distinct effector functions.

Materials and Methods

Antibodies and reagents

All chemical reagents were from Sigma-Aldrich unless otherwise specified. Primary and secondary antibodies used in this study are listed in Table 1. Other reagents: Opti-MEM (Thermo Fisher, 11,058,021) and Trypsin (Thermo Fisher, 27,250,018); Alexa Fluor® 488 or 568-conjugated Transferrin from Human Serum (ThermoFisher Scientific, T13342); rhodamine110, bis-(CBZ-L-isoleucyl-L-prolyl-L-arginine amide) dihydrochloride (BZiPAR; Thermo Fisher Scientific, R6505); LysoTracker® Blue DND-22 (Thermo Fisher Scientific, L7525; Cy3-STxB was a gift from Prof. Ludger Johannes (Institute Curie, Paris, France). Protease inhibitor (PI) cocktail (final concentrations: 40 μM pefablock SC (Merck, 11,429,876,001), 2.1 μM leupeptin (Merck, 11,529,048,001), 80 μM o-phenantroline (Merck,131,377), 1.5 μM pepstatin A (Merck, 11,524,488,001).
Table 1.

Antibodies used

ATG2Aab226931 Abcam1/500WB
ATG16L18089D6D5Cell Signaling Technology1/1000WB
ACTB/β-actinA2066 Sigma1/10,000WB
B4GALT1/β4-GALTHPA010807 Sigma1/200IF
EEA12411 Cell Signaling1/500; 1/1000IF WB
EGFRsc-031005Santa Cruz Biotechnology1/400; 1/1000IF WB
LAMP1H4A3H4A3USBiological Life Sciences1/500; 1/1000IF WB
MAP1LC3B/LC3NB100-2220 Novus Biologicals1/1000WB
SNX1611,48251/SNX1BD transduction Laboratories1/500IF
SNX6HPA049374 Atlas antibodies1/200IF
TFRC13–6800H68.4Invitrogen1/200IF
WIPI1H00055062-M023 C1Abnova1/1000WB
WIPI1W2394 Sigma1/1000WB
WIPI2HPA019852 Sigma1/500WB
WDR45B/WIPI3sc-514,194B-7Santa Cruz1/500WB
WDR45/WIPI4ab240905 Abcam1/1000WB
Cy3-conjugated AffiniPure donkey anti-mouse IgG (H + L) secondary antibody715–165-151 Jackson Immuno Research1/400IF
Cy3-conjugated AffiniPure donkey anti-rabbit IgG (H + L) secondary antibody711–165,152 Jackson Immuno Research1/400IF
Alexa Fluor® 488-conjugated AffiniPure donkey anti-mouse IgG (H + L) secondary antibody715–545-151 Jackson Immuno Research1/400IF
Alexa Fluor® 488-conjugated AffiniPure donkey anti-rabbit IgG (H + L) secondary antibody711–545-152 Jackson Immuno Research1/400IF
Alexa Fluor® 647-conjugated AffiniPure donkey anti-rabbit IgG (H + L) secondary antibody711–605-152 Jackson Immuno Research1/400IF
Alexa Fluor® 647-conjugated AffiniPure donkey anti-mouse IgG (H + L) secondary antibody715–605-151 Jackson Immuno Research1/400IF
IRDye® 800CW goat anti-mouse IgG (H + L)926–32,210 Li-Cor1/10,000WB
IRDye® 800CW goat anti-rabbit IgG (H + L)926–32,211 Li-Cor1/10,000WB
IRDye® 680RD goat anti-mouse IgG (H + L)926–68,070 Li-Cor1/10,000WB
IRDye® 680LT goat anti-rabbit IgG (H + L)926–68,071 Li-Cor1/10,000WB
Antibodies used

Complementary DNA (cDNA) constructs

Vectors expressing tagged-RAB proteins were purchased from Addgene: RFP-RAB4 (79,800; deposited by J.D. Johnson); DsRed-RAB11 (12,679; deposited by R. Pagano); mCherry-RAB7 (61,804; deposited by G. Voeltz); mCherry-RAB5 (49,201; deposited by G. Voeltz); DsRed-RAB9 (12,677; deposited by R. Pagano); mCherry-hLC3B-pcDNA3.1 (40,827; deposited by D. Rubinszstein). The following vectors were kindly provided by colleagues: EGFP-WIPI1 (pAR31CD vector) and EGFP-WIPI1[FAAG] (Tassula Proikas-Cezanne, Tübingen, Germany); pEGFP-FYVE2 (Harald Stenmark, Department of Molecular Cell Biology, Institute for Cancer Research, Oslo, Norway); mCherry-ML1N2 (Haoxing Xu, University of Michigan, Ann Arbor, USA). To generate mCherry-WIPI1, mCherry and WIPI1 fragments were amplified from pFA6a-mCherry-V5-KanMX6 (from Fulvio Reggiori, University Medical Center Groningen, Netherlands) and EGFP-WIPI1 plasmid, respectively, by using the primers listed in Table S1. Then, the two fragments were fused by using overlap extension-PCR and cloned into the pAR31CD vector between Age1 and EcoR1 restriction sites. To obtain EGFP-WIPI1[15Gly-CVVM] a sequence with 15 glycine and a CVVM motif were added to EGFP-WIPI1 plasmid by PCR using the primers listed in Table S1. The product was sub cloned into the pAR31CD-WIPI1 vector between Xmn1 and EcoR1 restriction sites.

Site-directed mutagenesis

All constructs were verified by DNA sequencing. EGFP-WIPI1 was used as DNA template for site-directed mutagenesis (QuikChange mutagenesis system, Agilent Technologies, 200,524) to generate EGFP-WIPI1[Sloop] and EGFP-WIPI1[ΔLoop]) following the manufacturer’s protocol using primers (Microsynth) listed in Table S1. For EGFP-WIPI1[Sloop] the sequence was STWSGYMGKMFMAATNYL changed into TSGYGMFMAATNYL (substituted amino acids are underlined and in bold). For EGFP-WIPI1[ΔLoop] a sequence of 18 amino acids was deleted (Figure 5). EGFP-WIPI1 was used as template to generate point mutations in the FRRG motif (R226A and R227A) and in the two histidine (H185A, H185N, H257Q and H257A) by using site-directed mutagenesis system and the primers containing desired mutations are listed in Table S1. Nonmutated template vector was removed from the PCR mixture through digestion by the enzyme Dpn1 for 1 h at 37°C. The product was purified using NucleoSpin PCR Clean-up (Macherey-Nagel, 740,609.50S) and transformed into Escherichia coli. Plasmid DNA was purified and sequenced. The site-directed mutagenesis system was also used to generate the siRNA-resistant cDNA for WIPI1. Forward and reverse sequences of the primers are listed in Table S1.

Cell culture, transfection and treatments

HK2 cells were grown in DMEM-HAM’s F12 (Thermo Fisher, 11,765,054) supplemented with 5% fetal calf serum (Gibco, 10,270,106), 50 U/mL penicillin/50 mg/mL streptomycin (ThermoFisher, 15,140,148), ITSE (5 μg/mL insulin, 5 μg/mL TF, 5 ng/mL selenium; LuBio Science, 00–101-100ML). Cells were grown at 37°C in 5% CO2 and at 98% humidity. HK2 cells were transfected with different plasmids using X-tremeGENETM HP DNA transfection reagent (Sigma-Aldrich, 6,366,546,001), unless otherwise specified, according to the manufacturer’s instructions, and incubated for 18–24 h before fixation or live cell imaging. The HK2 cell line was checked for mycoplasma contamination by a PCR-based method. All cell-based experiments were repeated at least three times.

RNA interference

HK2 cells were transfected with siRNA for 72 h using Lipofectamine® RNAiMax (Thermo Fisher Scientific, 13,778,150) according to the manufacturer’s instructions. Control cells (CTR2 in Figure. S1) were treated with identical concentrations of siGENOME Control Pool Non-Targeting from Dharmacon (D-001206-13-05). siRNAs targeting WIPI1, WIPI2, WDR45B/WIPI3, WDR45/WIPI4 and ATG16L1 were from Dharmacon (siGenome Human WIPI1 D-01820503; ON-TARGETplus Human WIPI2 J-020521; ON-TARGETplus Human WDR45B J-017119; ON-TARGETplus Human WDR45 J-019758; ON-TARGETplus Human ATG16L1 J-021033). siRNA targeting ATG2 was form Sigma (ATG2A 5ʹ- GCAUUCCCAGUUGUUGGAGUUCCUA-3ʹ; ATG2B 5ʹ-AGGUCUCUCUUGUCUGGCAUCUUUA-3ʹ). All siRNAs were used at a final concentration of 20 nM.

CRISPR-Cas9 gene editing

CRISPR sequences targeting the region that precedes the phosphoinositide-binding site of human WIPI1 were designed using the online Cas9 target design tool developed by the F. Zhang laboratory () [111,112]. The seed sequences preceding the protospacer adjacent motif (PAM) are the following: WIPI1 oligo 1–5′-CACCGCTTGAAGATGTGTACCGTCT-3′; WIPI1 oligo 2–5′-AAACAGACGGTACACATCTTCAAGC-3′; We used a sequence targeting luciferase as non-relevant single-guide RNA (sgRNA), (CTR1 in Figure. S1): luciferase oligo 1–5′-CACCGCTTCGAAATGTCCGTTCGGT-3′; and luciferase oligo 2–5′-AAACACCGAACGGACATTTCGAAGC-3′. Nucleotides in italics show the overhangs necessary for incorporation into the restriction site for BbsI of the LentiCRISPR-v2 vector expressing Cas9 and sgRNA (Addgene, 52,961; deposited by Feng Zhang). Lentiviruses were obtained from 293 T cells as previously described [113], were kindly provided from Fabio Martinon (University of Lausanne, Switzerland). HK2 cells were infected with lentiCRISPv2 viruses targeting WIPI1 (WIPI1 KO) or luciferase (CTR1). Positive cells were selected with 2 μg/mL puromycin for 15 days. The population was subjected to limiting dilution to obtain individual clones. WIPI1 expression was assessed by immunoblotting of whole-cell extracts (Figure. S1). To generate WIPI1 cDNA resistant to Cas9 digestion, a silent mutation was inserted in the PAM sequence (NGG) of the Cas9 target sequence (CCGAGACGGTACACATCTTCAAG), generating the sequence CGAGACGGTACACATCTTCAAG.

Endocytosis assays

TF binding and internalization

Cells were serum-starved for 60 min at 37°C, washed twice in cold PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4) with 1% BSA (Sigma-Aldrich A 8806) and incubated for 60 min on ice with 50 μg/ml of TF. The cells were fixed or chased in complete fresh HEPES-buffered medium at 37°C for the indicated time points. At the end of this incubation at 37°C, the cells were quickly acid-washed (150 mM NaCl, 10 mM acetic acid, pH 3.5) and then fixed.

TF recycling

HK2 cells were serum-starved for 60 min at 37°C, washed twice in cold PBS with 1% BSA, and then exposed to 100 μg/ml Alexa Fluor 488-TF for 60 min at 37°C (load). After extensive washing with complete fresh HEPES-buffered serum free-medium, the recycling of TF was followed by incubating the cells in TF-free complete medium (chase) for the indicated periods of time at 37°C. The cells were acid-washed (see above) before fixing.

Shiga toxin B-fragment transport

Transport of Shiga toxin B-fragment was investigated in fixed and living cells as described [68]. For experiments on fixed cells, cells on coverslips were placed on ice with 1 μg/ml Cy3-labeled B-fragment in HEPES-buffered DMEM and incubated for 30 min. Cells were washed three times with ice-cold culture medium and shifted in HEPES-buffered DMEM to either 19.5°C for 45 min or to 37°C in a CO2 incubator. After incubation for different periods of time, cells were washed three times with PBS containing 0.5 mM CaCl2 and 1 mM MgCl2, fixed with 3% PFA for 10 min, permeabilized with saponin, stained with the indicated primary and secondary antibodies, and then mounted. Slides were analyzed by confocal microscopy. For experiments on living cells, cells were plated on 42-mm glass cover slips. Cy3-labeled B-fragment was bound to these cells on ice and then internalized at 19.5°C, as described above, together with 10 μg/ml A488-TF. The cover slip was rapidly transferred to a POC-chamber on the heated stage of a confocal microscope, culture medium at 37°C was added, and image acquisition was started. Fluorescence intensity was measured with ImageJ software (NIH) on z-projections, either from the entire cell, or from the Golgi region, as defined by B4GALT1 labeling. The ratio was calculated as an index of Golgi localization as reported in Figure 3 B. A background correction factor was determined from cells that did not have internalized B-fragment.

EGFR degradation

HK2 cells were serum-starved for 24 h and then stimulated with 100 ng/ml EGF for the indicated periods of time. Immediately after stimulation, the cells were fixed or lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1% [v:v] Triton X-100 (Sigma-Aldrich, 648,462), 5 mM ethylenediaminetetraacetic acid, 200 mM Na3VO4, 50 mM NaF, 40 mM β-glycerophosphate, and protease inhibitors). The cell lysates were analyzed by SDS-PAGE and western blotting.

Immunofluorescence

In general, cells were fixed for 10 min in 4% paraformaldehyde in PBS. However, when preservation of tubular structures was required, cells were fixed for 8 min with 0.2% glutaraldehyde and 2% paraformaldehyde. After fixation, cells were permeabilized in 0.1% (w:v) saponin (Sigma-Aldrich, 558,255), 0.5% (w:v) BSA and 50 mM NH4Cl in PBS (blocking buffer) for 30 min at room temperature. The cells were incubated for 1 h with primary antibodies in blocking buffer, washed three times in PBS, incubated for 1 h with the secondary antibodies (Alexa Fluor-conjugated), washed three times in PBS, mounted with Mowiol (Sigma-Aldrich, 475,904-M) on slides and analyzed by confocal microscopy.

Confocal fluorescence microscopy, image processing, and colocalization analysis

HK2 cells were grown to 70% confluence on glass coverslips and immunofluorescence microscopy was performed as described above. The experiments were repeated at least three times and representative images are shown. The level of colocalization was analyzed by acquiring serial sections from about 80–100 cells per sample. Images were exported in TIFF format and processed as previously described [114]. Images of samples to be compared were acquired using the same settings (i.e., laser power, photomultiplier gain and pinhole size), avoiding pixel saturation. The images were processed in the same way using ImageJ software. Channels from each image were converted into 8-bit format and the ‘Auto Local Threshold’ Plug-in with the “Default” method was used to segment grayscale images, identify the structures of interest and subtract background. The ImageJ “Analyze Particles” Plug-in was then used to identify and count the total number of the structures (with an area above 0.10 μm2), e.g., for EEA1- and LAMP1-positive structures in the Figure 1E. TFRC, TF, EGF-R and BZiPAR fluorescence levels were quantified in CTR and WIPI1 KO cells using ImageJ. z-stack images were acquired and compressed into a single plane using the “maximum intensity Z-projection” function in ImageJ. Individual cells were selected using the freeform drawing tool to create a ROI (ROI). The “Measure” function provided the area, the mean gray value and integrated intensity of the ROI. The mean background level was obtained by measuring the intensity in three different regions outside the cells, dividing them by the area of the regions measured, and averaging the values obtained. To make a more accurate proportion background noise given off by unadhered dye has to be removed so per each cell the CTCF (corrected total cell fluorescence) was calculated using the formula: CTCF = integrated intensity of cell ROI − (area of ROI × mean fluorescence of background). To quantify the degree of colocalization, confocal z-stacks were acquired, single channels from each image in 8-bit format were thresholded to subtract background and then the “Just Another Colocalisation Plug-in” (JACOP) was used to measure the overlap coefficient according to Manders. Manders’ coefficient indicates an overlap of the signals and represents the degree of colocalization: where S1 represents signal intensity of pixels in the channel 1 and S2 represents signal intensity of pixels in the channel 2. The colocalization coefficients M1 and M2 describe contribution of each channel to the pixels. They are not dependent on the intensity of the overlapping pixels, but they are sensitive to background so a threshold has to be set [115]. For example, if the red-green pair of channels is selected and M1 and M2 are 1.0 and 0.2, respectively, this means that all red pixels colocalize with green pixels, but only 20% of green pixels colocalize with red ones. In our case M1 indicates the fraction of red pixels overlapping with green one, while M2 indicates the fraction of green pixels overlapping with the red ones. Furthermore, to measure the levels of colocalization of RABs and endosomal markers on tubules in cells overexpressing EGFP-WIPI1[Sloop] (Figure 6B,D) we used an approach based on the detection of signal edges by through the “Canny or Sobel filters” Plug-in for ImageJ [116]. The surrounded fields were filled to generate binary mask images. In this way, we were able to select tubules in order to separate signal from background, but also to determine a common region for analyzing both channels (i.e., red for Rabs and green for WIPI1[Sloop]). These mask images were then subjected to thresholding as described above and the levels of colocalization were evaluated with ImageJ JACOP Plug-in by calculating Manders’ coefficient. Confocal microscopy was performed on an inverted confocal laser microscope (Zeiss LSM 880 with airyscan) with a 63 × 1.4 NA oil immersion lens unless stated otherwise.

FRAP analysis

HK2 cells expressing EGFP-WIPI1[Sloop] and RFP-RAB4, DsRed-RAB11 and mCherry-RAB5 were plated into live-cell-imaging μ-dishes (Ibidi® Cell in Focus), incubated at 37°C in carbonate-free culture medium in a humidified temperature-controlled incubation chamber on a LSM880 confocal microscope. Cells were imaged using a 488 nm or 561 nm laser with a 63x NA 1.4 oil DIC M27 immersion objective (Zeiss). After collecting three pre‐bleaching images (pixel dwell 2.38 μsec), a selected ROI was bleached to < 80% of the original signal by a 488 nm (or 561 nm) laser pulse (100% power laser and pixel dwell 26.17 μsec). Post-bleaching images were collected at 1 s intervals for a total period of 150 s. At each time point, the mean fluorescence intensity of the bleached ROI was corrected by the background signal (regions from the same field but without any recognizable fluorescent structures) and by the fluorescence decay of a non-bleached area. The values were expressed as a percentage of the maximum fluorescence intensity in that ROI of the last pre-bleach image.

Gel electrophoresis and western blot

Cells were plated into 12-well tissue culture test plates (TPP) until they reached 90% confluency, except for KD-cells, which were cultured until 72 h after transfection with the siRNAs. Cells were then washed three times with ice-cold PBS (phosphate-buffered saline), scraped, and proteins were extracted in ice-cold lysis buffer (150 mM NaCl, 2 mM EDTA, 40 mM HEPES, and 1% Triton X-100 supplemented with phosphatase and protease inhibitor cocktail. Protein extracts were supplemented with 1/4 volume of 5x reducing sample buffer (250 mM Tris‐Cl, pH 6.8, 5% β-mercaptoethanol, 10% SDS, 30% glycerol, 0.02% bromophenol blue) and heated to 95 °C for 5 min. The samples were run on either 8%, 10% or 12.5% SDS-polyacrylamide gels (W x L x H: 8.6 × 6.8 x 0.15 cm). The stacking gels were prepared as follows: 6% acrylamide, 0.16% bis-acrylamide, 0.1 M Tris, pH 6.8, 0.1% SDS, 0.1% TEMED, 0.05% ammonium persulfate. Running gels were: 10% or 12.5% acrylamide, 0.27% or 0.34% bis-acrylamide, 0.38 M Tris, pH 8.8, 0.1% SDS (Applichem, 475,904-M), 0.06% TEMED (Applichem, A1148), 0.06% APS (Applichem, A2941). The gels were run at constant current (20–30 mA). Proteins were blotted onto nitrocellulose membrane by the semi-dry method for 80 min at 400 mA (Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell, Bio-Rad). After incubation with the primary antibody, signals were detected by secondary antibodies coupled to infrared dyes (LI-COR) and detected on a LI-COR Odyssey Infrared Imager. Images were exported as TIFF files and processed in Adobe Photoshop. Band intensity was quantified using ImageJ band analysis [117].

Membrane-cytosol fractionation

Cell lysis and fractionation were performed on ice using pre-chilled solutions. Centrifugations and incubations were carried out at 4°C. All buffers were supplemented with 1x protease inhibitor solution and 1 mM DTT directly before use. Cells were washed 3 times with PBS and pelleted for 5 min at 300 x g. The cell pellet was resuspended in 1 ml of buffer 1 (50 mM HEPES-KOH, pH 7.4, 100 mM KCl, 1 mM MgCl2) and cell lysis was performed by using a French press. The lysate was centrifuged at 800 x g for 15 min. The supernatant was centrifuged again at 1,000 x g for 15 min. The supernatant was centrifuged for 1 h at 100,000 x g in an ultracentrifuge. This final supernatant was used as the fraction of cytosolic proteins. The pellet of this last centrifugation was solubilized in 0.5 ml of buffer 2 (20 mM Tris HCl, pH 7.4, 0.4 M NaCl, 15% glycerol, 1.5% Triton X-100), shaken for 1 h at 1400 rpm and 4°C, and then centrifuged at 9,000 x g for 30 min. The supernatant was used as the membrane protein fraction.

Statistical analysis

Differences between the means have been evaluated by Student’s t-test unless otherwise specified. They are mentioned as relevant differences only when p < 0.01. Immunofluorescence experiments were repeated independently three times and at least 50 cells were analyzed from a single experiment. Representative images are shown. Western blotting experiments were repeated at least three times and representative blots are shown. Most data are presented as the means ± standard deviation (s.d.) unless otherwise specified. Click here for additional data file.
  118 in total

1.  Atg21 is a phosphoinositide binding protein required for efficient lipidation and localization of Atg8 during uptake of aminopeptidase I by selective autophagy.

Authors:  Per E Strømhaug; Fulvio Reggiori; Ju Guan; Chao-Wen Wang; Daniel J Klionsky
Journal:  Mol Biol Cell       Date:  2004-05-21       Impact factor: 4.138

Review 2.  Rab proteins and the compartmentalization of the endosomal system.

Authors:  Angela Wandinger-Ness; Marino Zerial
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-10-23       Impact factor: 10.005

3.  Recombinant protein rVP1 upregulates BECN1-independent autophagy, MAPK1/3 phosphorylation and MMP9 activity via WIPI1/WIPI2 to promote macrophage migration.

Authors:  Chiao-Chun Liao; Ming-Yi Ho; Shu-Mei Liang; Chi-Ming Liang
Journal:  Autophagy       Date:  2012-10-10       Impact factor: 16.016

4.  The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport.

Authors:  Anna C Rutherford; Colin Traer; Thomas Wassmer; Krupa Pattni; Miriam V Bujny; Jeremy G Carlton; Harald Stenmark; Peter J Cullen
Journal:  J Cell Sci       Date:  2006-09-05       Impact factor: 5.285

5.  GRAF1 forms a complex with MICAL-L1 and EHD1 to cooperate in tubular recycling endosome vesiculation.

Authors:  Bishuang Cai; Shuwei Xie; Steve Caplan; Naava Naslavsky
Journal:  Front Cell Dev Biol       Date:  2014-05-27

6.  Membrane protein recycling from the vacuole/lysosome membrane.

Authors:  Sho W Suzuki; Scott D Emr
Journal:  J Cell Biol       Date:  2018-03-06       Impact factor: 10.539

7.  Targeting of early endosomes by autophagy facilitates EGFR recycling and signalling.

Authors:  Jane Fraser; Joanne Simpson; Rosa Fontana; Chieko Kishi-Itakura; Nicholas T Ktistakis; Noor Gammoh
Journal:  EMBO Rep       Date:  2019-08-26       Impact factor: 8.807

8.  PIKfyve regulation of endosome-linked pathways.

Authors:  Jane de Lartigue; Hannah Polson; Morri Feldman; Kevan Shokat; Sharon A Tooze; Sylvie Urbé; Michael J Clague
Journal:  Traffic       Date:  2009-07       Impact factor: 6.215

9.  Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Authors:  Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

Review 10.  Membrane fission by dynamin: what we know and what we need to know.

Authors:  Bruno Antonny; Christopher Burd; Pietro De Camilli; Elizabeth Chen; Oliver Daumke; Katja Faelber; Marijn Ford; Vadim A Frolov; Adam Frost; Jenny E Hinshaw; Tom Kirchhausen; Michael M Kozlov; Martin Lenz; Harry H Low; Harvey McMahon; Christien Merrifield; Thomas D Pollard; Phillip J Robinson; Aurélien Roux; Sandra Schmid
Journal:  EMBO J       Date:  2016-09-26       Impact factor: 11.598

View more
  7 in total

Review 1.  Roles of PIKfyve in multiple cellular pathways.

Authors:  Pilar Rivero-Ríos; Lois S Weisman
Journal:  Curr Opin Cell Biol       Date:  2022-05-16       Impact factor: 8.386

2.  Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.

Authors:  Yuting Kuang; Na Ye; Armita Kyani; Mats Ljungman; Michelle Paulsen; Haijun Chen; Mingxiang Zhou; Christopher Wild; Haiying Chen; Jia Zhou; Nouri Neamati
Journal:  J Med Chem       Date:  2022-04-19       Impact factor: 8.039

3.  Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer.

Authors:  Song Wu; Ruilin Pan; Jibu Lu; Xiaoling Wu; Jingdong Xie; Hailin Tang; Xing Li
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

4.  Gracillin Shows Potential Efficacy Against Non-Small Cell Lung Cancer Through Inhibiting the mTOR Pathway.

Authors:  Yamei Li; Hai Liu; Xiaoxuan Liu; Bang Xiao; Minhong Zhang; Yaoling Luo; Mingchun Li; Jianqiong Yang
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

5.  CROP: a retromer-PROPPIN complex mediating membrane fission in the endo-lysosomal system.

Authors:  Thibault Courtellemont; Maria Giovanna De Leo; Navin Gopaldass; Andreas Mayer
Journal:  EMBO J       Date:  2022-04-25       Impact factor: 14.012

Review 6.  WIPI proteins: Biological functions and related syndromes.

Authors:  Mohammed Almannai; Dana Marafi; Ayman W El-Hattab
Journal:  Front Mol Neurosci       Date:  2022-09-09       Impact factor: 6.261

7.  A conserved ATG2 binding site in WIPI4 and yeast Hsv2 is disrupted by mutations causing β-propeller protein-associated neurodegeneration.

Authors:  Miranda Bueno-Arribas; Irene Blanca; Celia Cruz-Cuevas; Ricardo Escalante; María-Angeles Navas; Olivier Vincent
Journal:  Hum Mol Genet       Date:  2021-12-17       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.